Magellan Platform
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed

Gain Therapeutics platform using artificial intelligence and virtual screening for allosteric drug discovery.
Magellan is Gain Therapeutics' next-generation allosteric drug discovery platform, combining artificial intelligence with virtual screening to identify allosteric drug candidates.
The platform supports the company's development of allosteric small molecule therapies directed at protein misfolding targets.
Allorion Therapeutics

Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform
alloriontx.com
Jacobio Pharma

Induced Allosteric Drug Discovery Platform
jacobiopharma.com
Adds products that compete with one of Magellan Platform’s direct competitors but not with Magellan Platform itself. They are shaded, and Linked Through names the direct competitor each one competes with.
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider 
Founded 2015
Sells To Enterprise, Government
Pricing Model Recurring
Ownership Public
Linked Through Induced Allosteric Drug Discovery Platform
Provider 
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Linked Through Induced Allosteric Drug Discovery Platform
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed
Linked Through Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed


Marine microbial extract screening libraries supplying drug discovery researchers with diverse natural product chemistry for high-throughput screening.


Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.


Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.


Drug discovery platform from Tango Therapeutics that identifies synthetic lethal targets using CRISPR-based functional genomics screening.
Marine microbial extract screening libraries supplying drug discovery researchers with diverse natural product chemistry for high-throughput screening.

Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.

Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.

Drug discovery platform from Tango Therapeutics that identifies synthetic lethal targets using CRISPR-based functional genomics screening.
